FDA Scrutinizes Novo Nordisk: Reporting Lapses and Rising Safety Concerns with Ozempic & Wegovy
The FDA recently issued a warning letter to Novo Nordisk, the manufacturer of Ozempic and Wegovy, citing failures to adequately report potential adverse effects and deaths linked to the popular GLP-1 medications. This action underscores growing scrutiny surrounding these drugs as demand surges and potential risks come under closer examination.
The FDA’s Concerns: Delayed Reporting of Serious Events
The FDA’s warning, dated March 5, 2026, followed a post-marketing inspection of Novo Nordisk’s New Jersey facility in early 2025. The agency identified “serious violations” related to the timely reporting of adverse events. Specifically, the FDA cited three reported deaths among patients using semaglutide, the active ingredient in both Ozempic and Wegovy, including one case of suicide. The FDA clarified it has not determined if the drugs caused these events, but the reporting delays are the primary concern.
The Rise of Weight Loss Scams Exploiting GLP-1 Popularity
Alongside the FDA’s safety concerns, a parallel issue is emerging: a surge in scams capitalizing on the demand for GLP-1 medications. The Better Business Bureau (BBB) reports a significant increase in advertisements for supplements falsely claiming to deliver similar weight loss results. These scams often utilize deceptive tactics, including deepfake celebrity endorsements – such as a fabricated Oprah Winfrey advertisement – to mislead consumers.
Spotting a GLP-1 Scam: A Key Red Flag
The most significant indicator of a scam is the availability of treatment without a prescription. Legitimate GLP-1 prescriptions require a doctor’s oversight. The BBB advises consumers to thoroughly vet any company offering these medications without a prescription and to avoid sharing personal health or insurance information until legitimacy is confirmed.
Novo Nordisk’s Response and Future Outlook
Novo Nordisk acknowledged receiving the FDA’s warning letter and stated it has been “working diligently” to address the identified observations since February 2025. The company maintains it has taken significant steps to ensure compliance with reporting requirements and does not anticipate any disruption to production. Novo Nordisk welcomes further dialogue with the FDA to resolve the concerns.
What This Means for Patients
The FDA’s warning serves as a reminder of the importance of responsible medication use and the need for transparency in reporting adverse events. Patients considering or currently using Ozempic or Wegovy should discuss any concerns with their healthcare provider.
Frequently Asked Questions
What are GLP-1 medications?
GLP-1 medications, like Ozempic and Wegovy, are prescribed for both type 2 diabetes and weight loss.
What did the FDA warn Novo Nordisk about?
The FDA warned Novo Nordisk about failing to report potential side effects and deaths associated with Ozempic and Wegovy in a timely manner.
How can I avoid weight loss scams?
Be wary of any product advertised as a GLP-1 alternative that doesn’t require a prescription. Always consult with a healthcare professional.
Pro Tip: Always verify the legitimacy of any online pharmacy or healthcare provider before purchasing medications. Check for accreditation and read reviews.
Did you understand? The FDA’s warning letter is a public document available on the agency’s website. View the full warning letter here.
Updated: 3:04 PM PDT Mar 12, 2026